Investment Analyst
US$120 – US$200 / hr base salary
Posted 17 Sep 2026
Advertised as “Biotech Investment Analyst - Drug Asset & Company Assessment”
BranchFactor Summary
The original posting with the fluff stripped out
- Management level
- Individual contributor
- Employment
- Remote
- Contract
- Contract
| Base salary | US$120 – US$200 / hr |
|---|
This role is for one of our clients
Compensation: $120 - $200 per hour
We are partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.
Requirements
Responsibilities
- Create and critique rubrics that analyze commercial drugs and drug-development programs
- Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers
- Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions
- Apply your assessment across the pilot's set of companies (~5–10)
Requirements
- US-based biotech / healthcare investment analyst with a specialist-fund background
- Familiarity with biotech/pharma development programs
- Able to assess a drug asset and the company behind it end-to-end
- 5+ years evaluating biotech/pharma companies or assets
Engagement Details
- Duration: Approximately 10–20 hours over a 1–2 week pilot
- Remote — US-based
Why Participate
- Help improve expert AI evaluation of drugs and drug-development programs
- Recurring engagement for strong contributors
We consider all qualified applicants without regard to legally protected characteristics and provide reasonable accommodations upon request.